Related Experiment Video

Updated: Jun 9, 2026

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

AATF inhibits aberrant production of amyloid beta peptide 1-42 by interacting directly with Par-4

Qing Guo1, Jun Xie

  • 1Department of Physiology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA. qing-guo@ouhsc.edu

The Journal of Biological Chemistry
|November 25, 2003
PubMed

Insights

Apoptosis-antagonizing transcription factor (AATF) inhibits prostate apoptosis response-4 (Par-4) activity, preventing aberrant amyloid beta (Abeta) production. This finding offers a new therapeutic target for Alzheimer's disease (AD).

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Cellular Biology

Background:

  • Amyloid beta (Abeta) aggregation is an early event in Alzheimer's disease (AD) pathogenesis.
  • Prostate apoptosis response-4 (Par-4), a pro-apoptotic protein, is implicated in AD-related neuronal degeneration.
  • Apoptotic pathways may influence beta-amyloid precursor protein (APP) processing and Abeta production.

Purpose of the Study:

  • To investigate the interaction between AATF and Par-4 in neural cells.
  • To determine if AATF modulates Par-4-induced aberrant Abeta production.
  • To explore AATF as a potential therapeutic target for AD.

Main Methods:

  • Investigated AATF and Par-4 colocalization in neural cells.
  • Performed co-immunoprecipitation to confirm direct interaction between AATF and Par-4.
  • Utilized neuroblastoma IMR-32 cells to assess Abeta production and secretion.
  • Examined the effect of AATF co-expression on Par-4-induced Abeta-(1-42) production and secretion.

Main Results:

  • AATF colocalizes with Par-4 in both cytoplasmic and nuclear compartments of neural cells.
  • AATF directly and selectively interacts with Par-4 via its leucine zipper domain.
  • Par-4 overexpression induced aberrant Abeta production and secretion in IMR-32 cells.
  • Co-expression of AATF completely blocked Par-4-induced aberrant Abeta-(1-42) production and secretion.
  • AATF/Par-4 complex formation was crucial for AATF's inhibitory effect on Abeta secretion.

Conclusions:

  • AATF acts as an endogenous antagonist of Par-4 activity.
  • AATF effectively inhibits aberrant Abeta production and secretion under apoptotic conditions.
  • AATF represents a potential therapeutic target for mitigating Abeta pathology in Alzheimer's disease.

More Related Videos

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease15:23

Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease

Published on: May 13, 2010

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...